For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Authorities in Jharkhand are alarmed as, after five children, four blood donors also tested positive for HIV. The blood ...
Retesting of 259 donors being carried out after five children undergoing treatment for thalassemia tested positive for HIV, ...
"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback